uniQure NV QURE 深 沪
已收盘 11-13 16:00:00 美东时间
23.81
-0.820
-3.33%
华盛通- 最 高24.50
- 今 开24.50
- 成交量 139.45万股
- 最 低 23.3424
- 昨 收 24.63
- 总市值 167.00万
- 52周最高 51.7199
- 市盈率 静 --
- 换手率 1988.22%
- 52周最低 8.73
- 委 比 76.64%
- 总股本 7.01万
- 历史最高 82.49
- 量 比 0.85
- 振 幅 4.70%
- 历史最低 3.73
- 每 手 1
- 风险率 10.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多uniQure N.V.收涨5.02%，成交额2883.14万美元
11月10日，uniQure N.V.（QURE）收涨5.02%，报22.79美元，成交额2883.14万美元，市值15.98亿美元。 行情数据 • 开盘价：...
11-10 06:33
财报速睇 | uniQure NV 2026财年Q3营收0.05亿美元，同比增长40.4%；归母净利润亏损0.61亿美元，同比亏损缩窄24.0%
华盛资讯11月4日讯，uniQure NV公布2026财年Q3业绩，公司Q3营收0.05亿美元，同比增长40.4%，归母净利润亏损0.61亿美元，同比亏损缩窄24.0%。
11-04 20:34
uniQure Q3 EPS $(0.88) Beats $(0.92) Estimate, Sales $5.200M Miss $6.178M Estimate
uniQure (NASDAQ:QURE) reported quarterly losses of $(0.88) per share which beat the analyst consensus estimate of $(0.92) by 4.35 percent. This is a 36.23 percent increase over losses of $(1.38) per share from the same period last year. The company reported quarterly sales of $5.200 million which mi...
11-04 20:15
uniQure N.V.收跌7.49%，成交额1.55亿美元
11月3日，uniQure N.V.（QURE）收跌7.49%，报22.97美元，成交额1.55亿美元，市值15.93亿美元。 行情数据 • 开盘价：26.2...
11-03 06:31
uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease
uniQure's BLA for ifezuntirgene inilparvovec, a gene therapy for Huntington’s disease, has been accepted by the FDA with a PDUFA target action date of May 1, 2027. The application received Priority Review and may be discussed at an Advisory Committee meeting. If approved, it would be the first disease-modifying treatment for Huntington’s disease. The therapy uses a gene-silencing platform to target the huntingtin gene. The BLA is supported by Pha...
11-02 12:05
uniQure to Announce Third Quarter 2026 Financial Results
uniQure N.V. will report third quarter 2026 financial results on November 4, 2026, followed by a conference call at 8:30 a.m. ET. The event will be webcast on uniQure’s website, with a replay available for 90 days. Analysts can join the call by dialing (646) 307-1963 or (800) 715-9871 and entering conference ID 5075555. uniQure, a leader in gene therapy, has achieved historic milestones in treating hemophilia B and is advancing treatments for Hun...
10-28 11:05
uniQure N.V.收跌3.48%，成交额2170.71万美元
10月27日，uniQure N.V.（QURE）收跌3.48%，报21.65美元，成交额2170.71万美元，市值15.02亿美元。 行情数据 • 开盘价：...
10-27 05:35
uniQure N.V.收跌3.29%，成交额2840.43万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 05:36
美股大行评级 | 瑞银维持康宁“买入”评级，上调目标价至201美元；大摩维持泛林集团“超配”评级
今日重点评级关注：Needham：维持iRhythm Holdings"买入"评级，目标价从192美元升至194美元；HC Wainwright & Co.：维持5E Advanced Materials"买入"评级，目标价从3.5美元升至6.75美元
10-06 16:45
美股大行评级 | 潜在涨幅600.93%！Ascendiant Capital上调Aytu BioPharma目标价至15美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14.5美元升至15美元；摩根大通：维持Annexon"超配"评级，目标价从14美元升至15美元
10-01 19:18
